Westbourne Investment Advisors Inc. Buys 1,065 Shares of Johnson & Johnson $JNJ

Westbourne Investment Advisors Inc. raised its stake in shares of Johnson & Johnson (NYSE:JNJ) by 15.6% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 7,883 shares of the company’s stock after purchasing an additional 1,065 shares during the period. Westbourne Investment Advisors Inc.’s holdings in Johnson & Johnson were worth $1,204,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently made changes to their positions in JNJ. Nuveen LLC purchased a new position in shares of Johnson & Johnson in the first quarter valued at $1,369,188,000. Pacer Advisors Inc. lifted its position in Johnson & Johnson by 1,382.0% during the first quarter. Pacer Advisors Inc. now owns 3,030,084 shares of the company’s stock valued at $502,509,000 after purchasing an additional 2,825,626 shares during the last quarter. Assenagon Asset Management S.A. grew its stake in shares of Johnson & Johnson by 159.6% in the 2nd quarter. Assenagon Asset Management S.A. now owns 4,159,260 shares of the company’s stock worth $635,327,000 after buying an additional 2,557,388 shares in the last quarter. Kingstone Capital Partners Texas LLC bought a new stake in shares of Johnson & Johnson in the 2nd quarter worth about $401,420,000. Finally, Dimensional Fund Advisors LP raised its position in shares of Johnson & Johnson by 14.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 16,903,105 shares of the company’s stock valued at $2,803,042,000 after buying an additional 2,129,612 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $188.29 on Tuesday. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The stock’s fifty day moving average price is $184.47 and its 200-day moving average price is $169.03. The firm has a market cap of $453.65 billion, a P/E ratio of 18.17, a P/E/G ratio of 2.19 and a beta of 0.38. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $194.48.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The company had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. On average, equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Citigroup boosted their price objective on Johnson & Johnson from $213.00 to $215.00 and gave the stock a “buy” rating in a research note on Wednesday, October 15th. Guggenheim raised Johnson & Johnson from a “neutral” rating to a “buy” rating and boosted their target price for the company from $167.00 to $206.00 in a research report on Tuesday, September 23rd. Weiss Ratings restated a “buy (b)” rating on shares of Johnson & Johnson in a research report on Friday, October 31st. Wells Fargo & Company set a $212.00 price objective on shares of Johnson & Johnson and gave the company an “overweight” rating in a research report on Friday, October 3rd. Finally, HSBC raised their target price on shares of Johnson & Johnson from $210.00 to $215.00 and gave the stock a “buy” rating in a report on Thursday, October 16th. Three analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $199.05.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.